BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor EfficacyFrank Hilberg, Wolfgang J. Rettig|Cancer Research|2008Cited by 1.1k
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine KinasesFrank Hilberg, Norbert Kraut|Journal of Pharmacology and Experimental Therapeutics|2017Cited by 105
Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical modelsNiranjan Awasthi, Roderich E. Schwarz, Quinn Kaurich et al.|Frontiers in Oncology|2023Cited by 3